Update on pancreatic cancer treatment

Nurse Practitioner

Volumn 35, Issue 8, 2010, Pages 16-22

  Sun, Virginia ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

HUMAN; MORTALITY; MULTIMODALITY CANCER THERAPY; NURSE PRACTITIONER; NURSING EDUCATION; PANCREAS TUMOR; RADIOTHERAPY; REVIEW; RISK FACTOR;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; EDUCATION, NURSING, CONTINUING; HUMANS; NURSE PRACTITIONERS; PANCREATIC NEOPLASMS; RADIOTHERAPY; RISK FACTORS;

EID: 77958183723     PISSN: 03611817     EISSN: 15388662     Source Type: Journal    
DOI: 10.1097/01.NPR.0000383949.48853.8f     Document Type: Article

References (54)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
2. Horner M, Ries L, Krapcho M, et al., eds. National Cancer Institute: SEER Cancer Statistics Review, 1975-2006.
3. Silverman DT, Dunn JA, Hoover RN, et al. Cigarette smoking and pancreas cancer: a case-control study based on direct interviews. J Natl Cancer Inst. 1994;86(20):1510-1516.
4. Lynch HT, Smyrk T, Kern SE, et al. Familial pancreatic cancer: a review. Semin Oncol. 1996;23(2):251-275.
5. Whelan AJ, Bartsch D, Goodfellow PJ. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med. 1995;333(15):975-977.
6. Hahn SA, Greenhalf B, Ellis I, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst. 2003;95(3):214-221.
7. National Comprehesive Cancer Center (NCCN). Clinical Practice Guidelines in Oncology: Pancreatic Carcinoma. 2009.
8. Rosa JA, Van Linda BM, Abourizk NN. New-onset diabetes mellitus as a harbinger of pancreatic carcinoma. A case report and literature review. J Clin Gastroenterol. 1989;11(2):211-215.
9. Ogawa Y, Tanaka M, Inoue K, et al. A prospective pancreatographic study of the prevalence of pancreatic carcinoma in patients with diabetes mellitus. Cancer. 2002;94(9):2344-2349.
10. Russo S, Butler J, Ove R, Blackstock AW. Locally advanced pancreatic cancer: a review. Semin Oncol. 2007;34(4):327-334.
11. el-Kamar FG, Grossbard ML, Kozuch PS. Metastatic pancreatic cancer: emerging strategies in chemotherapy and palliative care. Oncologist. 2003;8(1):18-34.
12. Sheibani-Rad S, Velanovich V. Effects of depression on the survival of pancreatic adenocarcinoma. Pancreas. 2006;32(1):58-61.
13. Fras I, Litin EM, Pearson JS. Comparison of psychiatric symptoms in carcinoma of the pancreas with those in some other intra-abdominal neoplasms. Am J Psychiatry. 1967;123(12):1553-1562.
14. Holland JC, Korzun AH, Tross S, et al. Comparative psychological disturbance in patients with pancreatic and gastric cancer. Am J Psychiatry. 1986;143(8):982-986.
15. Joffe RT, Adsett CA. Depression and carcinoma of the pancreas. Can J Psychiatry. 1985;30(2):117-118.
16. Yaskin J. Nervous symptoms at earliest manifestations of cancer of the pancreas. JAMA 1931;96:1664-1668.
17. Carney CP, Jones L, Woolson RF, Noyes R Jr, Doebbeling BN. Relationship between depression and pancreatic cancer in the general population. Psychosom Med. 2003;65(5):884-888.
18. Kelsen DP, Portenoy R, Thaler H, Tao Y, Brennan M. Pain as a predictor of outcome in patients with operable pancreatic carcinoma. Surgery. 1997;122(1):53-59.
19. Passik SD, Roth AJ. Anxiety symptoms and panic attacks preceding pancreatic cancer diagnosis. Psychooncology. 1999;8(3):268-272.
20. Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S. The prevalence of psychological distress by cancer site. Psychooncology. 2001;10(1):19-28.
21. Labori KJ, Hjermstad MJ, Wester T, Buanes T, Loge JH. Symptom profiles and palliative care in advanced pancreatic cancer: a prospective study. Support Care Cancer. 2006;14(11):1126-1133.
22. Reyes-Gibby CC, Chan W, Abbruzzese JL, et al. Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation. J Pain Symptom Manage. 2007;34(3):244-252.
23. Chang VT, Hwang SS, Kasimis B. Longitudinal documentation of cancer pain management outcomes: a pilot study at a VA medical center. J Pain Symptom Manage. 2002;24(5):494-505.
24. Grosvenor M, Bulcavage L, Chlebowski RT. Symptoms potentially influencing weight loss in a cancer population. Correlations with primary site, nutritional status, and chemotherapy administration. Cancer. 1989;63(2):330-334.
25. McCorkle R, Quint-Benoliel J. Symptom distress, current concerns and mood disturbance after diagnosis of life-threatening disease. Soc Sci Med. 1983;17(7):431-438.
26. Portenoy RK, Thaler HT, Kornblith AB, et al. Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res. 1994;3(3):183-189.
27. Chen ML, Tseng HC. Symptom clusters in cancer patients. Supportive Care Cancer. 2006;14(8):825-830.
28. Gift AG, Stommel M, Jablonski A, Given W. A cluster of symptoms over time in patients with lung cancer. Nurs Res. 2003;52(6):393-400.
29. Walsh D, Rybicki L. Symptom clustering in advanced cancer. Support Care Cancer. 2006;14(8):831-836.
30. Krech RL, Walsh D. Symptoms of pancreatic cancer. J Pain Symptom Manage. 1991;6(6):360-367.
31. Davidson W, Ash S, Capra S, Bauer J, Cancer Cachexia Study Group. Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer. Clin Nutr. 2004;23(2):239-247.
32. Johnson CD. Pancreatic carcinoma: developing a protocol for multi-detector row CT. Radiology. 2001;220(1):3-4.
33. Halm U, Schumann T, Schiefke I, Witzigmann H, Mössner J, Keim V. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer. 2000;82(5):1013-1016.
34. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363(9414):1049-1057.
35. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg. 1997;225(5):621-633.
36. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4(6):567-579.
37. Gallagher SF, Zervos EE, Murr MM. Distal pancreatectomy. In: Von Hoff DD, Evans DB, Hruban RH, eds. Pancreatic Cancer. Sudbury, MA: Jones and Bartlett; 2005:299-312.
38. Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg. 1997;226(3):248-257.
39. Lambert LA, Birkmeyer JD. Reducing the risk of pancreaticoduodenectomy. In: Von Hoff DD, Evans DB, Hruban RH, eds. Pancreatic Cancer. Sudbury, MA: Jones and Bartlett; 2005:335-344.
40. Pliarchopoulou K, Pectasides D. Pancreatic cancer: current and future treatment strategies. Cancer Treat Rev. 2009;35(5):431-436.
41. Shah AP, Strauss JB, Abrams RA. Review and commentary on the role of radiation therapy in the adjuvant management of pancreatic cancer. Am J Clin Oncol. 2010;33(1):101-106.
42. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120(8):899-903.
43. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776-782.
44. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358(9293):1576-1585.
45. Herman JM, Swartz MJ, Hsu CC, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008;26(21):3503-3510.
46. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200-1210.
47. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403-2413.
48. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23(15):3509-3516.
49. Sultana A, Smith CT, Cunningham D, et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol. 2007;25(18):2607-2615.
50. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960-1966.
51. House MG, Choti MA. Palliative therapy for pancreatic/biliary cancer. Surg Clin North Am. 2005;85(2):359-371.
52. Domínguez Muñoz JE. Pancreatic enzyme therapy for pancreatic exocrine insufficiency. Curr Gastroenterol Rep. 2007;9(2):116-122.
53. Kuebler KK. The palliative care advanced practice nurse. J Palliat Med. 2003;6(5):707-714.
54. Meier DE, Beresford L. Advanced practice nurses in palliative care: a pivotal role and perspective. J Palliat Med. 2006;9(3):624-627.